← Back to Clinical Trials
Recruiting NCT05188014

NCT05188014 Exercise and the Menstrual Cycle in Type 1 Diabetes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05188014
Status Recruiting
Phase
Sponsor University of Alberta
Condition Type 1 Diabetes
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2022-03-15
Primary Completion 2027-06-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Luteal Phase Aerobic ExerciseFollicular Phase Aerobic Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2022-03-15 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Female participants with type 1 diabetes using oral contraceptives will be asked to wear a continuous glucose monitor for at least three days on two separate occasions (once during the last week of active pills and once during the no pill/placebo pill phase of the menstrual cycle). An exercise session (45 minutes of aerobic exercise at 60% VO2peak on a cycle ergometer) will take place at 5 pm on the second day of glucose monitoring.

Eligibility Criteria

Inclusion Criteria: * type 1 diabetes diagnosed for at least 1 year * regular menses * using monophasic oral contraceptives * residing in Edmonton, Alberta and able to visit the lab at the University of Alberta Exclusion Criteria: * HbA1c \> 9.9% * frequent and unpredictable hypoglycemia * change in insulin management strategy within two months of the study * use of an automated insulin delivery system * blood pressure \> 140/95 * history of cardiovascular disease * severe peripheral neuropathy * active proliferative retinopathy * use of medications (other than insulin) that would affect blood glucose levels * any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.)

Frequently Asked Questions

Who can join the NCT05188014 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05188014 currently recruiting?

Yes, NCT05188014 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Alberta to inquire about joining.

Where is the NCT05188014 trial being conducted?

This trial is being conducted at Edmonton, Canada.

Who is sponsoring the NCT05188014 clinical trial?

NCT05188014 is sponsored by University of Alberta. The trial plans to enroll 15 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology